At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
RenovoRx today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026, and host a conference call and webcast at 4:30 p.m. ET.